FY2022 EPS Estimates for Marinus Pharmaceuticals, Inc. Lifted by Cantor Fitzgerald (NASDAQ:MRNS)

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNSGet Rating) – Equities researchers at Cantor Fitzgerald boosted their FY2022 earnings per share (EPS) estimates for Marinus Pharmaceuticals in a research report issued on Wednesday, April 20th. Cantor Fitzgerald analyst C. Duncan now expects that the biopharmaceutical company will post earnings of ($0.34) per share for the year, up from their previous forecast of ($2.70).

Marinus Pharmaceuticals (NASDAQ:MRNSGet Rating) last announced its quarterly earnings data on Monday, March 21st. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.04. Marinus Pharmaceuticals had a negative net margin of 643.70% and a negative return on equity of 121.57%. The company had revenue of $1.52 million during the quarter, compared to analyst estimates of $2.64 million. During the same period in the previous year, the business earned ($0.55) EPS.

Other analysts have also recently issued reports about the stock. HC Wainwright restated a “buy” rating and set a $38.00 target price on shares of Marinus Pharmaceuticals in a research report on Tuesday, March 22nd. Truist Financial upped their target price on shares of Marinus Pharmaceuticals from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, March 22nd. JMP Securities increased their price objective on shares of Marinus Pharmaceuticals from $21.00 to $22.00 and gave the company a “market outperform” rating in a research note on Tuesday, March 22nd. StockNews.com began coverage on shares of Marinus Pharmaceuticals in a research report on Thursday, March 31st. They set a “sell” rating for the company. Finally, Zacks Investment Research raised shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, February 26th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $29.86.

Shares of MRNS stock opened at $7.51 on Friday. The company has a debt-to-equity ratio of 0.83, a current ratio of 3.25 and a quick ratio of 3.25. Marinus Pharmaceuticals has a 1 year low of $7.10 and a 1 year high of $19.83. The firm has a fifty day moving average price of $8.88 and a 200-day moving average price of $10.49. The company has a market cap of $277.98 million, a price-to-earnings ratio of -2.79 and a beta of 1.34.

Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. raised its stake in shares of Marinus Pharmaceuticals by 0.7% in the 4th quarter. BlackRock Inc. now owns 3,016,889 shares of the biopharmaceutical company’s stock valued at $35,841,000 after acquiring an additional 19,686 shares during the period. Suvretta Capital Management LLC grew its holdings in shares of Marinus Pharmaceuticals by 20.1% in the fourth quarter. Suvretta Capital Management LLC now owns 2,638,775 shares of the biopharmaceutical company’s stock valued at $31,349,000 after purchasing an additional 441,349 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Marinus Pharmaceuticals by 2.6% in the fourth quarter. Geode Capital Management LLC now owns 593,097 shares of the biopharmaceutical company’s stock valued at $7,045,000 after purchasing an additional 15,281 shares in the last quarter. Jefferies Group LLC grew its holdings in shares of Marinus Pharmaceuticals by 2,774.8% in the third quarter. Jefferies Group LLC now owns 439,764 shares of the biopharmaceutical company’s stock valued at $5,005,000 after purchasing an additional 424,467 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Marinus Pharmaceuticals by 1.8% in the third quarter. Goldman Sachs Group Inc. now owns 239,125 shares of the biopharmaceutical company’s stock valued at $2,721,000 after purchasing an additional 4,253 shares in the last quarter. 85.95% of the stock is currently owned by institutional investors and hedge funds.

Marinus Pharmaceuticals Company Profile (Get Rating)

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

Featured Articles

Earnings History and Estimates for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.